A greater proportion of CD8+ tumor-infiltrating T cells expressed PD-1, at 60% in CT26LacZ tumors and 84.3% in B16-F10 tumors, which increased to 85 and 94.3%, respectively, after NDV treatment. The gene discussed is CD8A; the disease is neoplasm.